CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aspen Pharmacare Holdings Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aspen Pharmacare Holdings Limited
Aspen Place, 9 Rydall Vale Park
Douglas Saunders Drive ,La Lucia Ridge
Phone: +27 315808600p:+27 315808600 LA LUCIA, South Africa Ticker: APNAPN
Business Summary
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Kuseni D.Dlamini 56 1/1/2017 4/1/2012
Group Chief Executive, Executive Director Stephen B.Saad 60 1/1/2014 1/1/1999
Group Finance Officer, Executive Director SeanCapazorio 59 1/1/2022 1/1/1999
12 additional Officers and Directors records available in full report.

Business Names
Business Name
APN
APNHY
Arixtra
24 additional Business Names available in full report.

General Information
Number of Employees: 8,867 (As of 6/30/2024)
Outstanding Shares: 444,233,285 (As of 6/30/2024)
Shareholders: 43,107
Stock Exchange: JNB
Fax Number: +27 112396111


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024